Shareholders' (Deficit) Equity - Summary of Stock Appreciation Rights (Details) - SARS [Member] $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Nov. 30, 2015 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Stock, Outstanding, Beginning Balance (in shares) | shares	1.3
Stock, Exercised (in shares) | shares	(0.4)
Stock, Canceled (in shares) | shares	(0.1)
Stock, Outstanding, Ending Balance (in shares) | shares	0.8
Stock, Exercisable, at November 30, 2015 (in shares) | shares	0.8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price, Beginning Balance (in USD per share) | $ / shares	$ 10.84
Weighted Average Exercise Price, Exercised (in USD per share) | $ / shares	13.24
Weighted Average Exercise Price, Canceled (in USD per share) | $ / shares	18.64
Weighted Average Exercise Price, Ending Balance (in USD per share) | $ / shares	8.70
Weighted Average Exercise Price, Exercisable at November 30, 2015 (in USD per share) | $ / shares	$ 8.67
Weighted Average Remaining Contractual Life, Outstanding at November 30, 2015	2 years 1 month
Weighted Average Remaining Contractual Life, Exercisable at November 30, 2015	2 years 1 month
Aggregate Intrinsic Value, Outstanding at November 30, 2015 | $	$ 7.4
Aggregate Intrinsic Value, Exercisable at November 30, 2015 | $	$ 7.3